TPST vs. XERS, MGNX, EPIX, RVNC, INZY, CRMD, AQST, ATAI, ENTA, and XBIT
Should you be buying Tempest Therapeutics stock or one of its competitors? The main competitors of Tempest Therapeutics include Xeris Biopharma (XERS), MacroGenics (MGNX), ESSA Pharma (EPIX), Revance Therapeutics (RVNC), Inozyme Pharma (INZY), CorMedix (CRMD), Aquestive Therapeutics (AQST), Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), and XBiotech (XBIT). These companies are all part of the "pharmaceutical preparations" industry.
Xeris Biopharma (NASDAQ:XERS) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
Xeris Biopharma presently has a consensus price target of $4.63, suggesting a potential upside of 140.89%. Tempest Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 681.25%. Given Xeris Biopharma's higher possible upside, analysts clearly believe Tempest Therapeutics is more favorable than Xeris Biopharma.
In the previous week, Tempest Therapeutics had 1 more articles in the media than Xeris Biopharma. MarketBeat recorded 2 mentions for Tempest Therapeutics and 1 mentions for Xeris Biopharma. Tempest Therapeutics' average media sentiment score of 1.87 beat Xeris Biopharma's score of 0.81 indicating that Xeris Biopharma is being referred to more favorably in the media.
Tempest Therapeutics has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.
Xeris Biopharma has a beta of 2.37, meaning that its stock price is 137% more volatile than the S&P 500. Comparatively, Tempest Therapeutics has a beta of -1.65, meaning that its stock price is 265% less volatile than the S&P 500.
Tempest Therapeutics has a net margin of 0.00% compared to Tempest Therapeutics' net margin of -37.58%. Xeris Biopharma's return on equity of -232.39% beat Tempest Therapeutics' return on equity.
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 4.6% of Xeris Biopharma shares are owned by company insiders. Comparatively, 3.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Xeris Biopharma received 47 more outperform votes than Tempest Therapeutics when rated by MarketBeat users. Likewise, 69.65% of users gave Xeris Biopharma an outperform vote while only 64.14% of users gave Tempest Therapeutics an outperform vote.
Summary
Xeris Biopharma beats Tempest Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Tempest Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tempest Therapeutics Competitors List
Related Companies and Tools
